JANX · NASDAQ
Janux Therapeutics (JANX) Stock Price & Fundamentals
Janux Therapeutics (JANX) closed at $1,446.49 on Oct 9, 2026, up 0.67% from the previous close of $1,436.85.
Share price, past year
1Y +40.64%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $1,446.49 |
| Sep 30, 2026 | $1,374.17 |
| Aug 31, 2026 | $1,323.46 |
| Jul 31, 2026 | $1,406.69 |
| Jun 30, 2026 | $1,354.62 |
| May 29, 2026 | $1,335.28 |
| Apr 30, 2026 | $1,238.03 |
| Mar 31, 2026 | $1,244.17 |
| Feb 27, 2026 | $1,190.77 |
| Jan 30, 2026 | $1,119.24 |
| Dec 31, 2025 | $1,047.93 |
| Nov 28, 2025 | $1,089.18 |
| Oct 31, 2025 | $1,090.10 |
Key statistics
- Market cap
- $88.35B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.64
- Revenue (TTM)
- $24.00M
- Net income (TTM)
- −$102.59M
- Shares outstanding
- 61.1M
- Dividend yield
- —
- 52-week range
- $1,011.87 – $1,446.49
Janux Therapeutics's market cap is $88.35B, based on a share price of $1,446.49 and 61.1M shares outstanding as of Jun 30, 2026.
Financials
Janux Therapeutics reported revenue of $10.00M for fiscal 2025, down 5.55% from fiscal 2024.
Janux Therapeutics reported a net loss of $113.63M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $10.00M | −5.6% | −$113.63M | −1,136.3% | −$1.83 | −$83.28M |
| FY2024ended Dec 31, 2024 | $10.59M | +31.0% | −$68.99M | −651.6% | −$1.28 | −$44.17M |
| FY2023ended Dec 31, 2023 | $8.08M | −6.1% | −$58.29M | −721.2% | −$1.32 | −$52.43M |
| FY2022ended Dec 31, 2022 | $8.61M | +136.8% | −$63.06M | −732.2% | −$1.52 | −$49.37M |
| FY2021ended Dec 31, 2021 | $3.64M | — | −$32.67M | −898.3% | −$1.39 | −$18.46M |
| FY2020ended Dec 31, 2020 | $0.00 | — | −$6.78M | — | −$7.41 | −$4.37M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $10.27M | −$21.97M | −$0.35 |
| Q1 FY2026ended Mar 31, 2026 | $3.73M | −$24.36M | −$0.39 |
| Q4 FY2025ended Dec 31, 2025 | $0.00 | −$31.95M | −$0.51 |
| Q3 FY2025ended Sep 30, 2025 | $10.00M | −$24.31M | −$0.39 |
| Q2 FY2025ended Jun 30, 2025 | $0.00 | −$33.86M | −$0.55 |
| Q1 FY2025ended Mar 31, 2025 | $0.00 | −$23.51M | −$0.38 |
| Q4 FY2024ended Dec 31, 2024 | $0.00 | −$20.22M | −$0.36 |
| Q3 FY2024ended Sep 30, 2024 | $439.00K | −$28.06M | −$0.51 |
Company profile
- Name
- Janux Therapeutics, Inc.
- Ticker
- JANX
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 10955 Vista Sorrento Parkway, Suite 200, San Diego, CA 92130
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001817713
Recent SEC filings
- Aug 6, 2026
- Aug 6, 2026
- Jun 23, 2026
- Jun 12, 2026
- May 7, 2026
- May 7, 2026
- Apr 28, 2026
- Feb 26, 2026
Frequently asked questions
What is Janux Therapeutics's stock price?
Janux Therapeutics (JANX) closed at $1,446.49 on Oct 9, 2026, up 0.67% from the previous close of $1,436.85.
What is Janux Therapeutics's market cap?
Janux Therapeutics's market cap is $88.35B, based on a share price of $1,446.49 and 61.1M shares outstanding as of Jun 30, 2026.
How much revenue does Janux Therapeutics make?
Janux Therapeutics reported revenue of $10.00M for fiscal 2025, down 5.55% from fiscal 2024.
Does Janux Therapeutics pay a dividend?
Janux Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Janux Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures